<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-SRDL85PO</identifier><date>1998</date><creator>Movrin-Stanovnik, Tadeja</creator><relation>documents/doc/S/URN_NBN_SI_doc-SRDL85PO_001.pdf</relation><relation>documents/doc/S/URN_NBN_SI_doc-SRDL85PO_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 105-108</format><identifier identifier_type="COBISSID_HOST">9649881</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-SRDL85PO</identifier><language>slv</language><publisher>Kancerološko združenje Slovenskega zdravniškega društva</publisher><publisher>Zveza slovenskih društev za boj proti raku</publisher><source>Onkološki vikend</source><rights>BY-NC-ND</rights><subject language_type_id="eng">Adverse effects</subject><subject language_type_id="eng">Contraindications</subject><subject language_type_id="eng">Diagnosis</subject><subject language_type_id="eng">Iodine radioisotopes</subject><subject language_type_id="eng">Therapy</subject><subject language_type_id="eng">Thyroid neoplasms</subject><title>Radioaktivni jod in rak ščitnice</title></Record>